Godaddy Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Godaddy Inc trades at $104.83 (market cap $13.07B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.69 (market cap $6.04B). The key difference: Godaddy Inc is far larger — about 2.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| GDDY | IOVA | |
|---|---|---|
Market Cap | $13.07B | $6.04B |
Volume | 1,831,274 | 14,805,993 |
Sector | Technology | Health |
52-Week High | $135.18 | $14.82 |
52-Week Low | $75.07 | $1.81 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | $15.75B | $5.97B |
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.7, up 7.7% in the last 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $4.95B in 2025 and net income of $875M, with consistent earnings beats in recent quarters. However, the stock faces headwinds from a securities class action lawsuit alleging misrepresentations about domain contract terms, with a lead plaintiff deadline of October 20, 2026.
The outlook is mixed: strong profitability and earnings momentum support upside, but legal risks and a consensus price target of $96.20 suggest caution. Investors should weigh robust fundamentals against potential litigation impacts and market sentiment shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →